Important Information for Geron Corporation Securities Purchasers: Rosen Law Firm Announces Class Action Lawsuit and Lead Plaintiff Deadline
New York, NY – March 26, 2025
Rosen Law Firm, a leading global investor rights law firm, reminds purchasers of Geron Corporation (NASDAQ: GERN) securities between February 28, 2024 and February 25, 2025, both dates inclusive (the “Class Period”), of the important May 12, 2025 lead plaintiff deadline. The lawsuit alleges that Geron Corporation issued materially misleading business information to the investing public.
Background on Geron Corporation
Geron Corporation is a biotechnology company focused on developing therapies for aging and age-related diseases. The Company’s lead product candidate, GRN163L, is an investigational telomerase inhibitor for the potential treatment of age-related diseases.
The Class Action Lawsuit
The complaint alleges that during the Class Period, Geron Corporation made false and/or misleading statements and/or failed to disclose material information about the Company’s business, operations, and prospects. Specifically, the lawsuit alleges that the Company failed to disclose:
- The negative results of a Phase 3 clinical trial of GRN163L, which showed that the drug did not meet its primary endpoint;
- The Company’s intention to discontinue development of GRN163L;
- The financial impact of these developments on the Company’s business and prospects.
As a result of these allegedly false and misleading statements, Geron Corporation’s securities traded at artificially inflated prices during the Class Period, causing investors harm.
What Does This Mean for Geron Corporation Securities Purchasers?
If you purchased Geron Corporation securities during the Class Period, you may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement. The lead plaintiff deadline is May 12, 2025. To obtain additional information, contact Rosen Law Firm.
How Will This Affect the World?
The outcome of this class action lawsuit could have far-reaching implications for the biotechnology industry and investors. If the allegations are proven true, it could lead to increased scrutiny and regulation of clinical trial data reporting, as well as increased transparency and disclosure requirements for biotech companies. It could also serve as a reminder for investors to carefully consider the risks and potential rewards of investing in the biotech sector.
Additionally, the outcome of this lawsuit could have a significant financial impact on Geron Corporation and its shareholders. If the Company is found liable for securities fraud, it could face significant damages and financial penalties.
Conclusion
Rosen Law Firm’s announcement of a class action lawsuit against Geron Corporation and the lead plaintiff deadline serves as a reminder for investors to be vigilant when investing in the biotech sector. The outcome of this lawsuit could have significant implications for the industry and investors, and those who purchased Geron Corporation securities during the Class Period should consider their options for potential compensation.
For more information, contact Rosen Law Firm at (866) 767-3653 or via email at [[email protected]](mailto:[email protected]).
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
